Document Detail

Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics.
MedLine Citation:
PMID:  23038766     Owner:  NLM     Status:  MEDLINE    
Kidney cancer is not a single disease; it is made up of a number of different types of cancer, including clear cell, type 1 papillary, type 2 papillary, chromophobe, TFE3, TFEB, and oncocytoma. Sporadic, nonfamilial kidney cancer includes clear cell kidney cancer (75%), type 1 papillary kidney cancer (10%), papillary type 2 kidney cancer (including collecting duct and medullary RCC) (5%), the microphalmia-associated transcription (MiT) family translocation kidney cancers (TFE3, TFEB, and MITF), chromophobe kidney cancer (5%), and oncocytoma (5%). Each has a distinct histology, a different clinical course, responds differently to therapy, and is caused by mutation in a different gene. Genomic studies identifying the genes for kidney cancer, including the VHL, MET, FLCN, fumarate hydratase, succinate dehydrogenase, TSC1, TSC2, and TFE3 genes, have significantly altered the ways in which patients with kidney cancer are managed. While seven FDA-approved agents that target the VHL pathway have been approved for the treatment of patients with advanced kidney cancer, further genomic studies, such as whole genome sequencing, gene expression patterns, and gene copy number, will be required to gain a complete understanding of the genetic basis of kidney cancer and of the kidney cancer gene pathways and, most importantly, to provide the foundation for the development of effective forms of therapy for patients with this disease.
W Marston Linehan
Related Documents :
21118976 - Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose...
19819096 - Managing uncertainty about treatment decision making in early stage prostate cancer: a ...
17922166 - Frustrated and confused: the american public rates its cancer-related information-seeki...
23898086 - Gene polymorphism of matrix metalloproteinase-12 and -13 and association with colorecta...
24528506 - Bladder cancer index: cross-cultural adaptation into spanish and psychometric evaluation.
14533846 - Decreased activity of cathepsins l + b and decreased invasive ability of pc3 prostate c...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2012-10-04
Journal Detail:
Title:  Genome research     Volume:  22     ISSN:  1549-5469     ISO Abbreviation:  Genome Res.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-05     Completed Date:  2013-04-11     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  9518021     Medline TA:  Genome Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2089-100     Citation Subset:  IM    
Urologic Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents
Carcinoma / drug therapy,  genetics*
Gene Expression Regulation, Neoplastic
Genes, Neoplasm
Genetic Predisposition to Disease
Kidney Neoplasms / drug therapy,  genetics*
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of changing oxygenation policies on retinopathy of prematurity in a neonatal unit in Argentin...
Next Document:  PUB-NChIP--"in vivo biotinylation" approach to study chromatin in proximity to a protein of interest...